What CGTA Research Group does

CGTA Research Group is a small United States-based non-profit organization, founded in 2012 and headquartered in Eagan, Minnesota, with a staff of 1-10. Its stated mission is to advance gene therapies into clinical trials for rare central nervous system (CNS) diseases — a narrowly defined translational research niche spanning preclinical development through first-in-human studies.

The organization is founder-led, with Michael D. Kaytor serving as President, Co-Founder & Investigator. No further management, scientific advisory, or board details are disclosed in the available data. There is no documentation of proprietary platforms, technology stack components, patents, partnerships, or clinical-stage programs in the input material; the primary referenced source returned only a verification/waiting screen rather than substantive company content.

Because CGTA Research Group is a non-profit, its operating economics are presumed to be grant- and donation-funded rather than commercial. No revenue, funding rounds, donor base, customer roster, or geographic footprint information is available, and the public-facing website (cgtaresearchgroup.org) was not retrievable as substantive content during this data collection. As a result, the practical analytical picture of the entity is limited to its mission statement, micro-scale footprint, and founder identity.

Name

CGTA Research Group

Website

https://cgtaresearchgroup.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

CGTA Research Group is a small US-based non-profit, founded in 2012 in Eagan, Minnesota, that works to advance gene therapies into clinical trials for patients with rare central nervous system diseases.

Ownership category

akta.pro rank

Product category

Gene Therapy Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology/CNS Gene Therapies (HLAAACAH)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Gene therapy research
• Rare CNS diseases
• Clinical trial development
• Non-profit research
• Translational research

Headquarters

HQ city

Eagan

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

CGTA Research Group is a non-profit organization that specializes in bringing gene therapies into clinical trials for rare CNS diseases. The group conducts translational research aimed at advancing novel gene therapy candidates into clinical-stage development for underserved rare neurological conditions.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Emerging players

• Taysha Gene Therapies: Clinical-stage gene therapy company focused exclusively on rare CNS diseases, developing AAV-based therapies for monogenic neurological disorders — directly comparable therapeutic focus to CGTA, though operating as a commercial entity rather than a non-profit.
• Lysogene: Gene therapy company focused exclusively on rare CNS diseases, developing AAV-based therapies for neurodegenerative disorders in pediatric populations — directly comparable indication and modality focus to CGTA.
• Passage Bio: Clinical-stage gene therapy company focused on rare monogenic CNS diseases, developing AAV-delivered therapies — comparable therapeutic and indication overlap with CGTA's mission, though structured as a venture-backed biotech.

Direct peers

• Cure SMA: Non-profit organization dedicated to accelerating treatments and a cure for spinal muscular atrophy, a rare neuromuscular disease, with active investment in gene therapy translation — directly comparable to CGTA in mission, structure, and focus on advancing rare disease gene therapies toward clinical trials.
• Charcot-Marie-Tooth Association: Non-profit focused on CMT, a rare inherited neurological disorder, funding research and advancing therapeutic candidates including gene therapies toward clinical trials — comparable to CGTA in mission, structure, and rare CNS disease gene therapy focus.
• AADC Research Trust: Small non-profit focused on aromatic L-amino acid decarboxylase (AADC) deficiency, a rare CNS disorder, with active involvement in advancing gene therapy clinical trials — closely mirrors CGTA's narrow rare CNS gene therapy focus and non-profit clinical translation model.
• Batten Disease Support and Research Association: Non-profit supporting research and clinical advancement for Batten disease, a group of rare neurodegenerative CNS disorders, including gene therapy approaches — comparable to CGTA as a rare CNS disease-focused patient/research organization with clinical translation objectives.

Broad incumbents

• REGENXBIO: Established gene therapy company developing AAV-based therapies including programs in rare CNS indications — operates as a broader incumbent in the gene therapy space where CGTA is a specialized non-profit research entity.
• Sarepta Therapeutics: Commercial-stage gene therapy company with approved and clinical-stage AAV therapies for rare neuromuscular and CNS-related diseases — operates in the same rare disease gene therapy space where CGTA is building pipeline assets.
• uniQure: Commercial gene therapy company with programs in rare neurological diseases including CNS-targeted AAV therapies — a broader incumbent in the same therapeutic space CGTA targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CGTA Research Group